Success Stories
Highlights of the PCI news focused on Penn commercialization accomplishments
Highlights of the PCI news focused on Penn commercialization accomplishments
Penn spinout Capstan Therapeutics unites decades of combined experience in groundbreaking CAR therapies with the latest advances in mRNA delivery technology to find new cures for cancer and other dise
Innervace, a regenerative medicine startup cofounded by Penn Medicine’s Kacy Cullen, PhD, and Douglas Smith, PhD raised up to $40 million in Series A financing.
The company was awarded FDA orphan drug designation for its experimental therapy, GTP-506, on the heels of the drug receiving rare pediatric disease designation.
This fall, the Penn Center for Innovation and Penn Engineering present three monthly sessions with expert speakers, who will discuss funding, pitching, and open source software for commercialization.
This fall, the Penn Center for Innovation and Penn Medicine present three monthly speaker sessions with experts in the field of Life Sciences investing, university startups, and intellectual property.
Tumors within the heart affect thousands of patients around the world annually, but prior to the ŌNŌ system, open-heart surgery was the only way to remove them.
Lumify Care and Neuralert have grown rapidly in terms of funding and product expansion.
Shinkei Systems cuts down on waste by reducing the likelihood that off-target species would be caught and killed, and streamlining the process to avoid waste.
Rosa's experience working in the lab and participating in the PCI Fellows program at Penn helped her gain valuable experience for her career at Deloitte.
Learn about Marion Leary and her mission to help health professionals pursue a career path in innovation.